Skip to main content

Next-Gen Delivery Technologies for Precise Neurotherapeutic Dosing

NeuraSeed BCI is revolutionizing the therapeutic treatment of brain tumors and a variety of neurological conditions by implanting micro-neurotechnology in previously inaccessible areas of the brain. 

Our goal is to provide an implantable delivery platform for FDA-approved therapeutics and electrical neuromodulation with real-time response monitoring.

Our technology is designed to integrate Convection-Enhanced Delivery (CED), Microelectrode Arrays (MEA) and Biological Micro-ElectroMechanical Systems (MEMS) to deliver chemotherapeutic and immunotherapeutic agents across the blood-brain-barrier while bypassing the gastrointestinal tract and liver, eliminating systemic side effects and vastly reducing exposure to drug toxicities.

This innovative technology is expected to allow for high bioavailability of neuroactive agents to target cells, improved signal-to-noise ratio, and immediate and sustained therapeutic effects.

Our patent-pending novel BCI is designed to collect functional electrophysiological, neurochemical, and biomarker data directly from within the deep brain. This real-time data can pave the way for the identification of novel therapeutic targets and advance the understanding of functional neural networks within white matter tracts and subcortical nuclei.

Overcoming the Blood-Brain Barrier

The greatest hurdle in conquering brain cancers and neurological disorders? The brain itself. The Blood-Brain Barrier (BBB) is a formidable shield of blood vessels and tissues that safeguards the brain from harmful invaders, like bacteria, viruses and toxins. While this defense mechanism is crucial for our well-being, it poses a significant challenge for delivering therapeutic medicines into the brain.

Our sophisticated technology is being developed to transport chemotherapeutic and immunotherapeutic agents directly across the blood-brain barrier. By avoiding the gastrointestinal tract and liver, this innovative approach is designed to eradicate side effects and significantly minimize exposure to drug toxicities, offering a safer, more efficient treatment experience.

Precise Targeting to Minimize Side Effects and Maximize Efficacy

One of the most significant obstacles in treating brain tumors is that cancer cells invade surrounding tissues in the brain, making it impossible to remove the tumor entirely. NeuraSeed BCI’s delivery system is designed to tackle this issue by strategically placing microfluidic pumps directly at the site requiring medication.  

This precise approach is intended to ensure medications reach the tumor site without affecting healthy brain tissue or other parts of the body. By offering targeted delivery, patients could benefit from more accurate medication doses, potentially minimizing or even eliminating side effects associated with systemic drug delivery.